Impact of the spread of COVID-19 on the economy, medical institutions and surgical cases
First written in FY2020-Q3. 10 of 20 entries say "Mitigated", first in FY2022-Q1. Latest entry: FY2026.
Medius Holdings moved to the "Worse" side of this theme in 2026, 6 years after the typical company in this theme (2020).
1 other company's latest entry also says "Reframed".
- FY2026ReframedAnnual report
「If a large-scale emerging infectious disease such as a novel influenza virus or COVID-19 occurs and the scale or speed of its spread significantly exceeds expectations, it could disrupt normal business operations through temporary business suspensions, delays in procurement, inventory accumulation and delays in collecting trade receivables, affecting the Group's sales and earnings.」
The disclosure has been reframed from the recent impact of COVID-19 on medical demand to business continuity risks associated with emerging infectious diseases generally, with COVID-19 cited as an example. - FY2025-H1MitigatedAnnual report
「During the interim consolidated accounting period, sales of operating-room-related products and other products performed well as the number of medical cases increased.」
Sales of operating-room-related products and other products performed well as the number of cases increased, and the trend toward a reduced direct impact of COVID-19 on medical demand has continued. - FY2024MitigatedAnnual report
「During the consolidated fiscal year, sales of operating-room-related products and other products performed well as medical demand recovered and sales expanded through the acquisition of new customers and other measures. Meanwhile, sales of infection-control products, including reagents used for COVID-19 testing and PPE (personal protective equipment), declined as demand stabilised.」
Against the backdrop of the change to a Class 5 infectious disease and other factors, medical demand recovered and sales of operating-room-related products and other products performed well, while demand for testing reagents and PPE stabilised and the direct business impact of COVID-19 showed signs of easing. - FY2024-Q3RestatedAnnual report
「During the cumulative third quarter of the consolidated fiscal year, sales of operating-room-related products and other products performed well as medical demand recovered compared with the same quarter of the previous year. Meanwhile, sales of infection-control products, including reagents used for COVID-19 testing and PPE (personal protective equipment), declined as demand stabilised.」
While sales of operating-room-related products and other products performed well as medical demand recovered, demand for testing reagents and PPE stabilised, and the disclosure continues to describe a trend toward a reduced direct business impact from infectious diseases. - FY2024-Q2MitigatedAnnual report
「During the cumulative second quarter of the consolidated fiscal year, sales of operating-room-related products and other products performed well as medical demand recovered compared with the same quarter of the previous year. Meanwhile, sales of infection-control products, including reagents used for COVID-19 testing and PPE (personal protective equipment), declined as demand stabilised.」
Sales of operating-room-related products and other products performed well as medical demand recovered, while sales of infection-control products, including COVID-19 testing reagents and PPE, declined as demand stabilised. The direct impact of COVID-19 on medical demand is showing signs of easing. - FY2024-Q1Recovery in medical demand, rising infections and continued burden of infection-control measuresAnnual report
「Although the legal classification of COVID-19, which had had a significant impact on medical institutions, changed to a Class 5 infectious disease under the Infectious Diseases Control Law and infections increased, medical demand has been recovering.」
The disclosure states that infections have increased since the change to a Class 5 infectious disease, while medical demand has recovered. Although the direct impact on medical demand is showing signs of easing, the burden on healthcare management from infection-control costs has continued separately. - FY2023MitigatedAnnual report
「The legal classification of COVID-19 changed in May 2023 to a Class 5 infectious disease under the Infectious Diseases Control Law, and medical demand has been recovering. However, the number of infections has begun to rise since May, and the situation remains unpredictable.」
Although the impact on medical institutions is showing signs of easing following the change in COVID-19's legal classification and the recovery in medical demand, increases in infections and some other effects remain. - FY2023-Q3MitigatedAnnual report
「During the nine-month period ended the third quarter of the current consolidated fiscal year, the impact of COVID-19 on medical institutions eased and medical demand began to recover, but the environment surrounding the Group remained uncertain, with concerns about higher costs resulting from surging resource prices due to the situation in Ukraine, rising prices caused by currency fluctuations, and other factors.」
The disclosure states that the impact of COVID-19 on medical institutions has eased and medical demand is beginning to recover as vaccination and infection-control measures have progressed. Meanwhile, intermittent waves of infection and uncertainty in the economic environment remain. - FY2023-Q2MitigatedAnnual report
「Although the impact of COVID-19 on medical institutions has been easing as vaccination and infection-control measures have progressed, intermittent waves of infection have continued.」
The impact of COVID-19 on medical institutions has been easing as vaccination and infection-control measures have progressed, and a recovery in medical demand was also described. Meanwhile, intermittent waves of infection and sluggish patient numbers in some areas remain. - FY2023-Q1MitigatedAnnual report
「Although the impact of COVID-19, including the decline in medical cases at medical institutions, has been easing as vaccination and infection-control measures have progressed, concerns remain over higher costs caused by factors including soaring resource prices due to the situation in Ukraine and inflation resulting from foreign-exchange fluctuations, and the outlook remains uncertain.」
The disclosure states that the impact of COVID-19, including the decline in medical cases at medical institutions, has been easing as vaccination and infection-control measures have progressed. Meanwhile, concerns over higher costs remain. - FY2022MitigatedAnnual report
「Although the impact of the spread of COVID-19 has been easing as medical institutions have advanced their infection-control measures, the effects of restrictions on patients seeking medical care and postponement of non-urgent surgeries, particularly in the Tokyo metropolitan area, have persisted. Inpatient and outpatient numbers have remained sluggish compared with pre-pandemic levels, affecting the operating conditions of medical institutions.」
Although the impact of the spread of infection has been easing as infection-control measures have advanced, the impact on medical institutions from restrictions on seeking medical care, postponed surgeries and sluggish patient numbers has continued. - FY2022-Q3MitigatedAnnual report
「Although the impact of the spread of COVID-19 has been easing as medical institutions have advanced their infection-control measures, the effects of restrictions on patients seeking medical care and postponement of non-urgent surgeries, particularly in the Tokyo metropolitan area, have persisted. Inpatient and outpatient numbers have remained sluggish compared with pre-pandemic levels, affecting the operating conditions of medical institutions.」
Although the impact of the spread of infection has been easing as medical institutions have advanced their infection-control measures, the effects of restrictions on seeking medical care, postponed surgeries and sluggish patient numbers have continued. - FY2022-Q2RestatedAnnual report
「Although conditions in the healthcare industry are improving compared with last year, the prolonged effects of reduced patient visits and postponed non-urgent surgeries, particularly in the Tokyo metropolitan area, have left inpatient and outpatient numbers still below pre-pandemic levels and are affecting the management of medical institutions.」
Although the effects of COVID-19, including sluggish patient numbers at medical institutions, restrictions on seeking medical care and postponed surgeries, are showing signs of improvement compared with the previous year, they have continued. - FY2022-Q1MitigatedAnnual report
「Although conditions are improving compared with last year, the effects of restrictions on patients seeking medical care and postponement of non-urgent surgeries, particularly in the Tokyo metropolitan area, have persisted and are affecting the operating conditions of medical institutions.」
Although the impact of COVID-19 on medical institutions is showing signs of improvement compared with the previous year, the effects of restrictions on seeking medical care and postponed surgeries have persisted. - FY2021RestatedAnnual report
「Although the decline in sales of medical supplies due to fewer outpatients and surgical and examination cases at medical institutions has continued as the COVID-19 pandemic has been prolonged, sales of infection-control products, including PPE (personal protective equipment) and reagents used for COVID-19 testing, have exceeded expectations.」
While the impact on medical supplies sales from fewer outpatients, surgeries and examination cases has continued, sales of infection-control products, including PPE and testing reagents, exceeded expectations, according to the disclosure. - FY2021-Q3RestatedAnnual report
「As new infections, hospitalisations and the number of severe cases continue to increase nationwide, and the increased burden on healthcare workers has become chronic, patients are required to be transferred from medical institutions treating COVID-19, according to their symptoms, and cooperation with supporting medical institutions is required to be strengthened. At medical institutions, operating conditions have become increasingly difficult owing to declines in outpatients and postponement of non-urgent surgeries.」
The disclosure continues to describe the increase in infections, hospitalisations and severe cases, the burden on healthcare workers, and the impact on medical institution management from fewer outpatients and postponed surgeries. - FY2021-Q2WorsenedAnnual report
「As new infections, hospitalisations and the number of severe cases continue to increase nationwide, and the increased burden on healthcare workers has become chronic, patients are required to be transferred from medical institutions treating COVID-19, according to their symptoms, and cooperation with supporting medical institutions is required to be strengthened. At medical institutions, operating conditions have become increasingly difficult owing to declines in outpatients and postponement of non-urgent surgeries.」
The disclosure states that the increase in new infections, hospitalisations and severe cases associated with the resurgence of infections, the chronic burden on healthcare workers, and the impact on medical institution management from fewer outpatients and postponed surgeries have become more serious. - FY2021-Q1WorsenedAnnual report
「In the healthcare industry, the government raised medical fees for hospitals accepting COVID-19 patients and expanded subsidies and lending programmes as measures to strengthen the healthcare delivery system. However, the effects of restrictions on patients seeking medical care and postponement of non-urgent surgeries have persisted at medical institutions, and difficult operating conditions have continued.」
The effects of restrictions on patients seeking medical care and postponement of non-urgent surgeries have persisted, and difficult operating conditions at medical institutions have continued, according to the disclosure. - FY2020MaterialisedAnnual report
「Medical institutions have been forced to establish and strengthen infection-control measures in order to treat patients with COVID-19, while restrictions on patients seeking medical care and postponement of non-urgent surgeries have had a significant impact on healthcare management.」
The impact on healthcare management from restrictions on seeking medical care and postponed surgeries associated with the spread of COVID-19 was described as part of the actual business environment. - FY2020-Q3First statedAnnual report
「Amid the impact of the spread of COVID-19, economic conditions in Japan and overseas have remained stagnant, and the outlook continues to be uncertain.」
In addition to the stagnation of the domestic and overseas economies caused by the spread of COVID-19, the decline in surgical cases was described as an actual business impact.